China Pharma Partners on Liver Disease Drug
Ticker: CPHI · Form: 8-K · Filed: Mar 29, 2024 · CIK: 1106644
| Field | Detail |
|---|---|
| Company | China Pharma Holdings, Inc. (CPHI) |
| Form Type | 8-K |
| Filed Date | Mar 29, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: partnership, drug-development, healthcare
TL;DR
China Pharma teams up with Hainan GengSheng to develop a new liver disease drug.
AI Summary
China Pharma Holdings, Inc. announced on March 27, 2024, that it has entered into a strategic cooperation agreement with Hainan GengSheng Pharmaceutical Co., Ltd. This agreement aims to jointly develop and market a new drug, focusing on the treatment of liver diseases. The collaboration will leverage the strengths of both companies in research, development, and market access.
Why It Matters
This partnership could lead to a new treatment option for liver diseases, potentially impacting a significant patient population and the pharmaceutical market for such conditions.
Risk Assessment
Risk Level: medium — Drug development is inherently risky, with high failure rates and long timelines, and the success of this collaboration is not guaranteed.
Key Players & Entities
- China Pharma Holdings, Inc. (company) — Registrant
- Hainan GengSheng Pharmaceutical Co., Ltd. (company) — Strategic partner
- March 27, 2024 (date) — Date of earliest event reported
FAQ
What is the specific liver disease targeted by this new drug development?
The filing does not specify the exact type of liver disease, only that the focus is on 'liver diseases'.
What are the respective roles of China Pharma Holdings and Hainan GengSheng in this collaboration?
The filing states it's a 'strategic cooperation agreement' to 'jointly develop and market', implying shared responsibilities in R&D and commercialization, but specific roles are not detailed.
Are there any financial commitments or investment details mentioned in the agreement?
The provided text of the 8-K filing does not contain specific financial commitments or investment details regarding this agreement.
What is the expected timeline for the development and potential market launch of this drug?
The filing does not provide any timeline for the drug development or market launch.
Has China Pharma Holdings, Inc. had previous collaborations or partnerships in drug development?
This specific 8-K filing focuses on the new agreement and does not provide historical context on previous collaborations.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-03-29 16:05:34
Filing Documents
- ea0202916-8k_chinapharma.htm (8-K) — 23KB
- 0001213900-24-027972.txt ( ) — 193KB
- cphi-20240327.xsd (EX-101.SCH) — 3KB
- cphi-20240327_lab.xml (EX-101.LAB) — 33KB
- cphi-20240327_pre.xml (EX-101.PRE) — 22KB
- ea0202916-8k_chinapharma_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On March 27, 2024, China Pharma Holdings, Inc. (the " Company ") received a notification from the NYSE American (the " Exchange ") stating that the Company is back in compliance with the NYSE American continued listing standards. Specifically, the Company has resolved the continued listing deficiency with respect to low selling price set forth in Section 1003(f)(v) of the NYSE American Company Guide referenced in the letter from the Exchange dated September 27, 2023, following a 1-for-5 reverse stock split on March 6, 2024. The below compliance (".BC") indicator will no longer be disseminated and the Company will be removed from the list of NYSE American noncompliant issuers on the website. However, the Company is cautioned by the Exchange that there is no cure period in the event of the following noncompliance and the NYSE American can commence delisting proceedings and immediately suspend trading in the event that the Company's common stock trades at levels viewed to be abnormally low and no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 29, 2024 CHINA PHARMA HOLDINGS, INC. By: /s/ Zhilin Li Name: Zhilin Li Title: President and Chief Executive Officer